- Home
- HBB vs SGHT Comparison
HBB vs SGHT Comparison
Compare HBB & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- SGHT
- Stock Information
- Founded
- HBB 1904
- SGHT 2011
- Country
- HBB United States
- SGHT United States
- Employees
- HBB N/A
- SGHT N/A
- Industry
- HBB Home Furnishings
- SGHT Medical Specialities
- Sector
- HBB Consumer Discretionary
- SGHT Health Care
- Exchange
- HBB Nasdaq
- SGHT Nasdaq
- Market Cap
- HBB 292.6M
- SGHT 304.4M
- IPO Year
- HBB 2017
- SGHT 2021
- Fundamental
- Price
- HBB $19.33
- SGHT $3.70
- Analyst Decision
- HBB
- SGHT Buy
- Analyst Count
- HBB 0
- SGHT 6
- Target Price
- HBB N/A
- SGHT $6.80
- AVG Volume (30 Days)
- HBB 49.0K
- SGHT 238.3K
- Earning Date
- HBB 10-30-2024
- SGHT 11-07-2024
- Dividend Yield
- HBB 2.31%
- SGHT N/A
- EPS Growth
- HBB 107.04
- SGHT N/A
- EPS
- HBB 1.88
- SGHT N/A
- Revenue
- HBB $647,834,000.00
- SGHT $79,543,000.00
- Revenue This Year
- HBB $4.60
- SGHT $2.18
- Revenue Next Year
- HBB N/A
- SGHT $8.14
- P/E Ratio
- HBB $10.69
- SGHT N/A
- Revenue Growth
- HBB 5.30
- SGHT N/A
- 52 Week Low
- HBB $14.34
- SGHT $2.58
- 52 Week High
- HBB $31.78
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- HBB 31.99
- SGHT 33.29
- Support Level
- HBB $18.54
- SGHT $3.86
- Resistance Level
- HBB $20.11
- SGHT $4.11
- Average True Range (ATR)
- HBB 0.90
- SGHT 0.19
- MACD
- HBB 0.33
- SGHT 0.05
- Stochastic Oscillator
- HBB 31.85
- SGHT 6.25
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.